Table of Content

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP-DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IS THE DOMINANT DRUG IN ANTIDEPRESSANTS MARKET
3.2.2. DEEP BRAIN STIMULATOR IS EXPECTED TO GROW FAST AMONG OTHER DEVICES OVER THE FORECAST PERIOD
3.2.3. COGNITIVE BEHAVIOR THERAPY (CBT) IS THE LARGEST CONTRIBUTOR TO ANTIDEPRESSANTS THERAPIES MARKET

4. MARKET DYNAMICS
4.1. MARKET DEFINITION & SCOPE
4.2. MARKET DRIVERS
4.2.1. RISE IN THE NUMBER OF DEPRESSION PATIENTS
4.2.2. INCREASE IN AGING POPULATION
4.2.3. RISING CONSCIOUSNESS OF DEPRESSION AS A MEDICAL DISORDER
4.2.4. SURGE IN SALES OF ANTIDEPRESSANTS
4.3. MARKET RESTRAINTS
4.3.1. HIGH COST OF DEPRESSION THERAPY
4.3.2. PATENT EXPIRATION FACED BY THE COMPANIES
4.3.3. DELAY IN PRODUCT LAUNCHES
4.4. MARKET OPPORTUNITIES
4.4.1. HUGE MARKET POTENTIAL
4.4.2. MORE PREFERENCE FOR PERSONNEL THERAPY & DEVICE TREATMENT
4.5. MARKET CHALLENGES
4.5.1. STIFF COMPETITION FROM THE GENERIC DRUGMAKERS

5. MARKET BY ANTIDEPRESSANTS DRUGS
5.1. SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs)
5.2. TRICYCLIC ANTIDEPRESSANTS (TCA)
5.3. MONOAMINE OXIDASE INHIBITORS (MAOIs)
5.4. ATYPICAL ANTIDEPRESSANTS
5.5. SELECTIVE SEROTONIN REUPTAKE INHIBITORS
5.6. BENZODIAZEPINES
5.7. ANTICONVULSANTS
5.8. BETA-BLOCKERS
5.9. OTHER ANTIDEPRESSANTS DRUGS

6. MARKET BY DEVICES
6.1. DEEP BRAIN STIMULATORS
6.2. FISHER WALLACE STIMULATORS
6.3. TRANSCRANIAL MAGNETIC STIMULATOR
6.4. OTHER DEVICES

7. MARKET BY THERAPIES
7.1. COGNITIVE BEHAVIOR THERAPY (CBT)
7.2. ELECTROCONVULSIVE THERAPY (ECT)
7.3. RATIONAL EMOTIVE BEHAVIOR THERAPY (REBT)
7.4. OTHER THERAPIES

8. KEY ANALYTICS
8.1. PORTER’S FIVE FORCE MODEL
8.1.1. THREAT OF NEW ENTRANTS
8.1.2. THREAT OF SUBSTITUTE
8.1.3. BARGAINING POWER OF SUPPLIERS
8.1.4. BARGAINING POWER OF BUYERS
8.1.5. THREAT OF COMPETITIVE RIVALRY
8.2. OPPORTUNITY MATRIX
8.3. VENDOR LANDSCAPE
8.4. VALUE CHAIN ANALYSIS
8.4.1. FOR DRUGS
8.4.2. FOR DEVICES
8.5. KEY BUYING CRITERIA

9. GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1. UNITED STATES
9.1.2. CANADA

10. COMPETITIVE LANDSCAPE
10.1. MARKET SHARE ANALYSIS
10.2. COMPANY PROFILE
10.2.1. ABBOT LABORATORIES
10.2.2. ALLERGAN PLC
10.2.3. BOEHRINGER INGELHEIM GMBH
10.2.4. BRAINSWAY
10.2.5. ELI LILLY AND COMPANY
10.2.6. F. HOFFMANN-LA ROCHE LTD.
10.2.7. GLAXOSMITHKLINE
10.2.8. H. LUNDBECK AS
10.2.9. MAYO CLINIC
10.2.10. NEURONETICS
10.2.11. PFIZER

List of Tables
TABLE 1 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY COUNTRY, 2019-2027, (IN $ MILLION)
TABLE 2 LANDSCAPE OF DRUG EXPIRY AND LAUNCHES IN THE UNITED STATES
TABLE 3 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY ANTIDEPRESSANTS DRUGS, 2019-2027, (IN $ MILLION)
TABLE 4 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY DEVICES, 2019-2027, (IN $ MILLION)
TABLE 5 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY THERAPIES, 2019-2027, (IN $ MILLION)
TABLE 6 OPPORTUNITY MATRIX
TABLE 7 VENDOR LANDSCAPE
TABLE 8 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY COUNTRY, 2019-2027 (IN $ MILLION)

List of Figures
FIGURE 1 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET SHARE, BY DRUGS, 2018 & 2027 (%)
FIGURE 2 SNRIs MARKET, 2019 - 2027 (IN $ MILLION)
FIGURE 3 DEEP BRAIN STIMULATORS MARKET, 2019-2027 (IN $ MILLION)
FIGURE 4 COGNITIVE BEHAVIOR THERAPY (CBT) MARKET ($ MILLION)
FIGURE 5 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY COGNITIVE BEHAVIOR THERAPY (CBT), 2019-2027, (IN $ MILLION)
FIGURE 6 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY ELECTROCONVULSIVE THERAPY (ECT), 2019-2027, (IN $ MILLION)
FIGURE 7 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY RATIONAL EMOTIVE BEHAVIOR THERAPY (REBT), 2019-2027, (IN $ MILLION)
FIGURE 8 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, OTHER THERAPIES, 2019-2027, (IN $ MILLION)
FIGURE 9 PORTER’S FIVE FORCE MODEL
FIGURE 10 VALUE CHAIN OF ANTIDEPRESSANT DRUGS
FIGURE 11 VALUE CHAIN ANALYSIS FOR DEVICE MARKET
FIGURE 12 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, REGIONAL OUTLOOK, 2018 & 2027, (%)
FIGURE 13 UNITED STATES ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, 2019-2027 (IN $ MILLION)
FIGURE 14 CANADA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, 2019-2027 (IN $ MILLION
FIGURE 15 MARKET SHARE OF ANTIDEPRESSANTS DRUG MANUFACTURERS (PERCENTAGE OF SALES), 2018



List of Figures


FIGURE 1 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET SHARE, BY DRUGS, 2018 & 2027 (%)
FIGURE 2 SNRIs MARKET, 2019 - 2027 (IN $ MILLION)
FIGURE 3 DEEP BRAIN STIMULATORS MARKET, 2019-2027 (IN $ MILLION)
FIGURE 4 COGNITIVE BEHAVIOR THERAPY (CBT) MARKET ($ MILLION)
FIGURE 5 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY COGNITIVE BEHAVIOR THERAPY (CBT), 2019-2027, (IN $ MILLION)
FIGURE 6 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY ELECTROCONVULSIVE THERAPY (ECT), 2019-2027, (IN $ MILLION)
FIGURE 7 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY RATIONAL EMOTIVE BEHAVIOR THERAPY (REBT), 2019-2027, (IN $ MILLION)
FIGURE 8 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, OTHER THERAPIES, 2019-2027, (IN $ MILLION)
FIGURE 9 PORTER’S FIVE FORCE MODEL
FIGURE 10 VALUE CHAIN OF ANTIDEPRESSANT DRUGS
FIGURE 11 VALUE CHAIN ANALYSIS FOR DEVICE MARKET
FIGURE 12 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, REGIONAL OUTLOOK, 2018 & 2027, (%)
FIGURE 13 UNITED STATES ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, 2019-2027 (IN $ MILLION)
FIGURE 14 CANADA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, 2019-2027 (IN $ MILLION
FIGURE 15 MARKET SHARE OF ANTIDEPRESSANTS DRUG MANUFACTURERS (PERCENTAGE OF SALES), 2018

 

List of Tables


TABLE 1 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY COUNTRY, 2019-2027, (IN $ MILLION)
TABLE 2 LANDSCAPE OF DRUG EXPIRY AND LAUNCHES IN THE UNITED STATES
TABLE 3 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY ANTIDEPRESSANTS DRUGS, 2019-2027, (IN $ MILLION)
TABLE 4 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY DEVICES, 2019-2027, (IN $ MILLION)
TABLE 5 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY THERAPIES, 2019-2027, (IN $ MILLION)
TABLE 6 OPPORTUNITY MATRIX
TABLE 7 VENDOR LANDSCAPE
TABLE 8 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY COUNTRY, 2019-2027 (IN $ MILLION)